Sign in
Taking peopleNo phase

Evaluation of Visual Outcomes, Complications, and Neuroadaptation Following Bilateral Implantation of enVista Envy Trifocal Intraocular Lenses

Key facts

Who runs it
Pomeranian Medical University Szczecin
Where
Poland1 site in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
People taking part
20 people, planned
Started
1 Feb 2026
Expected to end
Feb 2029
Type of study
Interventional
Treatments tested
  • cataract surgery
Record updated
10 July 2026

Who can take part

Age
50 years to 75 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • Bilateral cataract or refractive lens exchange candidates
  • Presbyopia and/or hyperopia
  • Preoperative corneal astigmatism less than 1.00 diopter (D)
  • Absence of ocular diseases other than cataract
  • High motivation to achieve spectacle independence
  • Patients willing to accept the possibility of mild photic phenomena, such as glare and halos

Who cannot take part

  • Ocular Conditions:; Glaucoma; Amblyopia; Macular diseases (including macular degeneration and other macular pathology); Angle kappa greater than 0.5 mm; Dry eye disease; Corneal disorders; Pupil abnormalities; Irregular astigmatism; Ocular motility disorders or strabismus; Pupil diameter < 2.5 mm under photopic conditions or > 6.0 mm under mesopic conditions; Abnormalities of the capsular bag or zonular apparatus, including pseudoexfoliation syndrome (PEX)
  • Psychological and Personality Factors:; Patients with psychiatric disorders that may interfere with study participation or outcome assessment; Patients dissatisfied with progressive addition lenses (progressive spectacles); Patients with dyslexia or a history of stroke; Type A personality traits (perfectionists)
  • Patients will also be excluded if the calculated IOL power falls outside the available range of +6.00 D to +34.00 D or if they have a history of laser vision correction surgery
  • Lifestyle Factors:; Patients with unrealistic expectations regarding postoperative visual outcomes; Individuals whose professions require highly precise visual performance, such as pilots, professional drivers, architects, or similar occupations; Patients satisfied with using spectacles for near vision; Age greater than 75 years (due to potential difficulties with neuroadaptation to new visual conditions)

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 50 and 75 years old?

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The enVista Envy intraocular lens (IOL) manufactured by Bausch + Lomb is a new multifocal intraocular lens based on diffractive optics. It was registered with the Polish Office for Registration of Medicinal Products, Medical Devices and Biocidal Products in September 2025. The lens also bears the CE mark, indicating that it is approved for marketing and use within the European Union.

Read full original descriptionShow less

Its innovative design is based on a smooth, continuous transition between diffractive rings, allowing patients to achieve excellent visual quality at far, intermediate, and near distances while reducing the incidence and severity of unwanted photic phenomena such as glare and halos. Thanks to this technology, patients may achieve better uncorrected visual acuity, reduced dependence on spectacles, and faster neuroadaptation.

The Second Department of Ophthalmology is the first center in Poland to be offered participation in a clinical study evaluating the safety and effectiveness of the enVista Envy IOL. The planned study will provide the first clinical experience with this lens in Poland and contribute to expanding knowledge regarding modern intraocular lens technologies.

Twenty patients will be selected according to predefined inclusion and exclusion criteria. Preoperative assessment will include a comprehensive ophthalmic examination and IOL power calculation. Cataract surgery will be performed using bimanual MICS (Micro-Incision Cataract Surgery) phacoemulsification. Surgery in the fellow eye will be performed one month after the first procedure.

Before surgery and during follow-up visits at 1, 3, and 6 months postoperatively, the following assessments will be performed: routine ophthalmic examination, intraocular pressure (IOP) measurement, visual evoked potentials (VEP), monocular and binocular uncorrected distance visual acuity (UDVA), distance best-corrected visual acuity (DBCVA) at 4 meters, intermediate visual acuity (66 cm) and near visual acuity (40 cm), both corrected and uncorrected, monocularly and binocularly (logMAR charts), binocular contrast sensitivity testing, and defocus curve assessment.

Intraoperative and postoperative complications, quality of vision (using the standardized Quality of Vision Questionnaire [QoV] and the Near Activity Vision Questionnaire [NAVQ]), speed of neuroadaptation, spectacle independence, and the occurrence of photic phenomena such as glare and halos will also be analyzed.

The group in the trial

  • 20 patients (40 eyes)Treatment being tested

    Patients who meet all inclusion criteria and none of the exclusion criteria.

    Treatment: cataract surgery

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Fit questions
Built from NCT07696130, who can take part
Record updated
10 July 2026